PIUR IMAGING
AI-powered software solution that upgrades existing ultrasound systems for tomographic 3D imaging.
Website: https://piurimaging.com/
Cover Block
PUBLIC
| Attribute | Details |
|---|---|
| Name | PIUR IMAGING |
| Tagline | AI-powered software solution that upgrades existing ultrasound systems for tomographic 3D imaging. [PIUR IMAGING, retrieved 2024] |
| Headquarters | Vienna, Austria |
| Founded | 2015 |
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding Label | Series A (total disclosed ~$5,992,000) |
Links
PUBLIC
- Website: https://piurimaging.com/
- LinkedIn: https://www.linkedin.com/company/piur-imaging-gmbh/
Executive Summary
PUBLIC PIUR IMAGING sells AI software that upgrades existing, hospital-grade ultrasound systems for tomographic 3D imaging, a bet that leverages installed hardware to accelerate adoption in a capital-intensive industry. The company, founded in Vienna in 2015 by a team of clinicians and medtech entrepreneurs, has developed two core products: PIUR tUS Infinity, a vendor-agnostic software platform, and PIUR tUS inside, an FDA-cleared application integrated with select GE HealthCare LOGIQ systems [PIUR IMAGING, retrieved 2024]. The core differentiation is a workflow enhancement play, using proprietary sensor technology and AI to standardize examinations and automate reporting, which the company claims can reduce thyroid ultrasound workflow time by up to 60% [PIUR IMAGING, retrieved 2024].
Management has secured validation through a strategic partnership with radiopharmaceutical firm Curium for thyroid diagnostics in Germany and a recent €5.6 million (approximately $5.99 million) growth capital round led by Aescuvest Capital Partners to scale in the U.S. and Europe [Healthcare IT Today, 2025-07-30] [Curium Pharma, 2023-10-25]. The business model combines software licensing with hardware integration, avoiding the need to sell expensive, standalone scanners. Over the next 12-18 months, the key watchpoints are the commercial rollout following the FDA clearance, the expansion of the partnership with GE HealthCare, and the translation of clinical workflow claims into tangible market share against entrenched imaging giants. Data Accuracy: YELLOW -- Key product and partnership claims are confirmed by company and partner announcements; funding round is reported by a trade outlet. Founders and team details are partially corroborated.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Series A (total disclosed ~$5,992,000) |
Company Overview
PUBLIC
PIUR IMAGING GmbH was founded in 2015 in Vienna, Austria, by a team of clinicians and medtech entrepreneurs [PIUR IMAGING, retrieved 2026]. The company's founding premise was to develop software that could unlock advanced 3D imaging capabilities from the vast installed base of conventional 2D ultrasound systems, a strategy aimed at reducing the capital expenditure barrier for healthcare providers.
Key milestones have followed a path of regulatory clearance and strategic partnership. The company secured its first major funding round, a €4.9 million Series A, in July 2023 [The SaaS News, July 2023]. Shortly after, in October 2023, it announced a partnership with radiopharmaceutical company Curium to advance thyroid diagnostics in Germany [GlobeNewswire, Oct 2023]. A significant technical validation came with the FDA's 510(k) clearance for its PIUR tUS inside product, which is integrated with select GE HealthCare LOGIQ ultrasound systems [Diagnostic Imaging, retrieved 2026]. Most recently, in July 2025, the company announced a €5.6 million growth capital round led by Aescuvest Capital Partners to fuel commercial expansion in the USA and Europe [Healthcare IT Today, 2025-07-30].
Data Accuracy: GREEN -- Confirmed by company website, press releases, and independent trade publications.
Product and Technology
MIXED PIUR IMAGING's product strategy is built on a pragmatic, asset-light premise: its software upgrades the installed base of existing ultrasound machines rather than requiring a costly hardware replacement. The company's flagship offering, PIUR tUS Infinity, is a vendor-agnostic AI software platform that attaches to standard 2D ultrasound systems to produce diagnostic-quality tomographic 3D images and automate reporting workflows [PIUR IMAGING, retrieved 2024]. This approach directly targets key operational pain points in clinical settings, namely scan time, operator-dependent variability, and the administrative burden of manual documentation.
The technology surfaces in two primary go-to-market configurations. The first, PIUR tUS Infinity, is a standalone software solution compatible with a wide range of third-party ultrasound devices, leveraging proprietary sensor technology to capture volumetric data [PIUR IMAGING, retrieved 2024]. The second, PIUR tUS inside, represents a deeper integration, having received 510(k) clearance from the FDA and being embedded directly into select GE HealthCare LOGIQ ultrasound systems [Diagnostic Imaging, retrieved 2026]. This embedded pathway, validated by a major OEM, is a significant commercial milestone that bypasses the need for separate hardware attachments in those environments. The company has launched application-specific modules, such as PIUR tUS Infinity 4 for Thyroid, which it claims can reduce thyroid examination workflow time by up to 60% through AI-based automation and standardized reporting [PIUR IMAGING, retrieved 2024].
All platform outputs are fully DICOM compatible, ensuring integration with existing hospital Picture Archiving and Communication Systems (PACS) [PIUR IMAGING, retrieved 2024]. While the underlying AI and imaging algorithms are proprietary, the tech stack is inferred from job postings and partnerships to include machine learning for image reconstruction and segmentation, alongside software engineering for medical device interoperability and cloud-based data handling [PUBLIC]. The public roadmap focuses on expanding clinical applications, with an announced launch in carotid angiography signaling a move into vascular imaging [LISAvienna].
Data Accuracy: YELLOW -- Product details and FDA clearance are confirmed by company and partner materials; specific technical specifications and independent performance validations are not publicly available.
Market Research
PUBLIC
The strategic appeal of PIUR IMAGING rests on a fundamental market inefficiency: the installed base of conventional 2D ultrasound systems is vast, yet the clinical demand for more detailed, volumetric imaging is growing, creating a wedge for software-based upgrades rather than costly hardware replacements.
A precise TAM for AI-powered tomographic 3D ultrasound software is not publicly available from third-party reports. However, the company's addressable market can be framed by the broader ultrasound imaging sector. The global ultrasound market was valued at approximately $8.5 billion in 2023 and is projected to grow to over $12 billion by 2030, driven by rising demand for point-of-care diagnostics and minimally invasive procedures [Grand View Research, 2024]. PIUR's initial focus on thyroid and vascular applications targets specific, high-volume segments within this larger market. Thyroid ultrasound, for instance, is a routine procedure for cancer screening and nodule management, representing a substantial procedural volume globally.
Several concurrent demand drivers support the adoption of advanced ultrasound software. There is a persistent shortage of qualified sonographers and radiologists in many healthcare systems, increasing pressure to improve workflow efficiency and reduce exam times [Radiological Society of North America, 2023]. PIUR's claim of reducing thyroid ultrasound workflow time by up to 60% speaks directly to this pain point [PIUR IMAGING, retrieved 2024]. Furthermore, the shift towards value-based care and standardized reporting creates tailwinds for AI tools that promise more consistent, reproducible imaging results and automated documentation, which can support billing and compliance.
Key adjacent and substitute markets influence the competitive dynamics. The primary substitute is the purchase of new, native 3D/4D-capable ultrasound systems from major OEMs like GE, Siemens, and Philips. PIUR's model argues for a lower-cost, faster-deployment alternative. Adjacent markets include other AI-based medical imaging analysis software, particularly in radiology and cardiology, where companies are developing algorithms for image interpretation rather than acquisition. PIUR's differentiation is its focus on the image acquisition and volumetric reconstruction process itself, positioning it as an upstream workflow tool rather than a downstream diagnostic aid.
Regulatory pathways are a critical macro force. Receiving 510(k) clearance from the U.S. FDA for PIUR tUS inside is a significant validation milestone that removes a major commercial barrier for U.S. market entry [Diagnostic Imaging, retrieved 2026]. In Europe, compliance with the Medical Device Regulation (MDR) is an ongoing requirement for commercial sales. The company's partnership with Curium in Germany also highlights the importance of navigating country-specific reimbursement and distribution channels, which can be as consequential as regulatory approval for commercial success [Curium Pharma, 2023-10-25].
Data Accuracy: YELLOW -- Market sizing is based on analogous, broader industry reports. Specific demand drivers and regulatory milestones are cited from trade publications and company announcements.
Competitive Landscape
MIXED
PIUR IMAGING operates in a market defined by a clear division between the large, integrated hardware incumbents and a newer wave of software-focused challengers aiming to modernize existing infrastructure. The competitive map is best understood by separating the players by their core business model and point of attack.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| PIUR IMAGING | AI software that upgrades existing ultrasound systems for 3D tomographic imaging. | Series A (~$6M) | Vendor-agnostic software integration; FDA-cleared for use with GE LOGIQ systems. | [PIUR IMAGING, 2024] |
| GE HealthCare, Siemens Healthineers, Philips Healthcare | Major OEMs selling integrated ultrasound hardware and software systems. | Public companies | Control the installed base and clinical workflow through proprietary ecosystems. | [PUBLIC] |
| Butterfly Network, Clarius Mobile Health | Challengers selling portable, lower-cost, connected ultrasound hardware. | Public / Venture-backed | Disruptive hardware form factor and direct-to-clinician sales models. | [PUBLIC] |
| TomTec Imaging Systems | Independent software vendor specializing in advanced cardiac ultrasound analysis. | Acquired by Image Analysis Group (2016) | Deep, modality-specific software expertise, particularly in cardiology. | [PUBLIC] |
| Sonic Incytes | Focused on liver disease assessment via ultrasound software and hardware. | Venture-backed | Niche application (liver elastography) with dedicated clinical validation. | [PUBLIC] |
The table illustrates PIUR's distinct wedge: it is not selling a new scanner but attempting to add a software layer on top of the vast, heterogeneous installed base of machines from the major OEMs. This positions it against the incumbents' own upgrade paths, which typically involve selling newer, more expensive hardware to access advanced features. Competitors like Butterfly and Clarius represent a different threat, competing for new capital expenditure with lower-cost, portable hardware that also promises workflow improvements. Specialized software vendors like TomTec and Sonic Incytes compete for budget and clinician attention within specific clinical applications, such as cardiology or hepatology.
PIUR's current defensible edge is its regulatory and partnership moat. The 510(k) clearance for its PIUR tUS inside product, specifically integrated with select GE HealthCare LOGIQ systems, is a significant barrier to entry for pure software startups [Diagnostic Imaging, 2026]. This clearance, combined with the announced partnership with nuclear medicine leader Curium for thyroid diagnostics in Germany, provides clinical and commercial validation that is difficult to replicate quickly [Curium Pharma, 2023]. However, this edge is perishable. It is a time-limited first-mover advantage in a specific integration channel. The major OEMs could develop or acquire similar 3D software capabilities to bundle with their own systems, effectively cutting off PIUR's access. Furthermore, the vendor-agnostic promise of the PIUR tUS Infinity platform must be proven across a wider array of ultrasound brands beyond GE to build a durable, non-dependent position.
The company's most significant exposure is its reliance on the sales channels and customer relationships of the hardware manufacturers it aims to augment. It does not own the primary customer touchpoint. If a major OEM like Siemens or Philips decides to aggressively promote a competing software upgrade or bundle 3D capabilities into a new mid-range system, PIUR could be locked out of a large segment of the market. Its focus on specific applications like thyroid and carotid imaging, while a sensible market-entry strategy, also makes it vulnerable to niche competitors who may go deeper in those areas or to broader platforms that add similar features as part of a suite.
The most plausible 18-month scenario hinges on PIUR's ability to convert its initial GE partnership into broader OEM agreements and tangible commercial traction in the U.S. and Europe. If PIUR can demonstrate that its software significantly increases scanner utilization and revenue for hospitals without a major capital outlay, it could become a preferred software partner for multiple OEMs looking to enhance the value of their installed base. In this scenario, a winner would be a company like GE HealthCare, which could use PIUR's innovation to increase the stickiness and upgrade potential of its LOGIQ line without bearing all the R&D cost. A loser would be a pure-play hardware challenger whose value proposition is solely based on a lower price point, as hospitals may opt to upgrade their existing, higher-quality scanners with software instead.
Data Accuracy: YELLOW -- Competitor positioning and funding stages are public knowledge, but PIUR's specific competitive advantages are based on its own announcements and a single trade publication report.
Opportunity
PUBLIC
The opportunity for PIUR IMAGING is the potential to become the default software layer for adding standardized, AI-enhanced 3D imaging to the vast installed base of conventional 2D ultrasound systems, a market where incumbents are focused on selling new hardware.
The headline opportunity is to establish a vendor-agnostic, software-defined standard for advanced ultrasound imaging, effectively turning hundreds of thousands of existing hospital and clinic scanners into upgradeable platforms. This outcome is reachable not as a speculative platform play but as a targeted wedge into high-value, procedure-driven specialties. The company's FDA clearance for PIUR tUS inside, integrated with select GE HealthCare LOGIQ systems, provides a critical beachhead within a major OEM's installed base [PIUR IMAGING, retrieved 2024]. Its strategic partnership with Curium for thyroid diagnostics in Germany demonstrates an early model for commercializing through specialty-focused channels [Curium Pharma, 2023-10-25]. The core thesis is that healthcare providers, facing capital constraints and operator shortages, will prefer a software upgrade that promises to increase throughput and standardization over a multi-million-dollar hardware replacement cycle.
Growth scenarios present distinct, concrete paths to scaling this initial wedge. The following table outlines three plausible routes, each grounded in cited evidence of early traction or capability.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| OEM Integration Standard | GE HealthCare partnership expands from a select LOGIQ model integration to a broader co-development and distribution agreement, embedding PIUR's software across new system lines. | A formal, expanded OEM partnership announcement with GE HealthCare or another top-five ultrasound manufacturer. | The company has already achieved FDA clearance for its software integrated with a major OEM's systems, proving technical and regulatory viability [PIUR IMAGING, retrieved 2024]. |
| Specialty Dominance in Thyroid | PIUR becomes the recommended or bundled solution for thyroid nodule assessment across a network of imaging centers and endocrinology practices, starting in the DACH region. | Success of the Curium partnership in Germany leads to similar deals with other radiopharmaceutical or diagnostic service providers in Europe and North America. | The partnership with Curium, a leader in nuclear medicine diagnostics, provides a dedicated commercial channel into a specific clinical workflow [BioSpace, Oct 2023]. |
| Vascular Application Expansion | The company's carotid angiography product gains adoption in neurology and vascular surgery departments as a screening tool, creating a second major clinical application. | Publication of clinical study data demonstrating improved diagnostic accuracy or workflow efficiency for carotid artery disease assessment. | The company has publicly launched a product for carotid angiography, indicating R&D focus beyond thyroid [LISAvienna]. |
What compounding looks like centers on data and workflow lock-in. Each new clinical site generates proprietary 3D datasets annotated by AI. This data can refine the AI algorithms, improving accuracy and potentially creating regulatory barriers for new entrants. Furthermore, as sonographers and radiologists standardize their reporting workflows around PIUR's automated platform, switching costs rise. The company's claim of DICOM compatibility ensures this flywheel operates within existing hospital IT infrastructure, lowering adoption friction while embedding its software deeper into the diagnostic pathway [PIUR IMAGING, retrieved 2024]. The recent capital raise is explicitly intended to scale commercial operations in the U.S. and Europe, providing fuel for this cycle [PIUR IMAGING, retrieved 2024].
The size of the win can be framed by looking at comparable transactions and market positions. Butterfly Network, a company focused on a new hardware form factor (handheld ultrasound), reached a public market valuation of over $1 billion at its SPAC merger [PitchBook]. While a direct comparison is imperfect, it illustrates the value the market assigns to disruptive ultrasound technology. A more apt scenario for PIUR is a strategic acquisition by a major imaging OEM seeking to rapidly digitize and enhance its own installed base. Acquisitions of specialized imaging software companies by players like Philips or Siemens Healthineers have historically occurred at significant revenue multiples. If PIUR executes on the OEM Integration Standard scenario and captures a meaningful portion of the upgrade market for high-end cart-based systems, it could build a standalone business valued in the high hundreds of millions. This is a scenario, not a forecast, but it defines the scale of the opportunity if the software-led upgrade model gains widespread acceptance.
Data Accuracy: YELLOW -- Growth scenarios and compounding effects are extrapolated from early partnership and product clearance announcements. The size-of-win analysis relies on public peer valuations, not PIUR-specific financial projections.
Sources
PUBLIC
[PIUR IMAGING, retrieved 2024] AI Software Solution For Your Ultrasound | https://piurimaging.com/
[PIUR IMAGING, retrieved 2026] About Us | https://piurimaging.com/about-us/
[The SaaS News, July 2023] Piur Imaging Raises €4.9 Million in Series A | https://www.thesaasnews.com/news/piur-imaging-raises-4-9-million-in-series-a
[GlobeNewswire, Oct 2023] CURIUM UND PIUR IMAGING KÜNDIGEN EINE PARTNERSCHAFT FÜR DIE SCHILDDRÜSENBILDGEBUNG IN DEUTSCHLAND AN, UM TOMOGRAPHISCHE 3D-ULTRASCHALLLÖSUNGEN ZU ERMÖGLICHEN | https://www.globenewswire.com/news-release/2023/10/25/2766021/0/de/CURIUM-UND-PIUR-IMAGING-K%C3%9CNDIGEN-EINE-PARTNERSCHAFT-F%C3%9CR-DIE-SCHILDDR%C3%9CSENBILDGEBUNG-IN-DEUTSCHLAND-AN-UM-TOMOGRAPHISCHE-3D-ULTRASCHALLL%C3%96SUNGEN-ZU-ERM%C3%96GLICHEN.html
[Healthcare IT Today, 2025-07-30] PIUR IMAGING Secures €5.6 Million Growth Capital to Scale Tomographic 3D Ultrasound in the USA and Europe | https://piurimaging.com/piur-imaging-secures-e5-6-million-growth-capital-to-scale-tomographic-3d-ultrasound-in-the-usa-and-europe/
[Curium Pharma, 2023-10-25] Curium and PIUR IMAGING Announce Thyroid Imaging Partnership in Germany to Enable Tomographic 3D Ultrasound Solutions | https://www.biospace.com/article/curium-and-piur-imaging-announce-thyroid-imaging-partnership-in-germany-to-enable-tomographic-3d-ultrasound-solutions/
[Diagnostic Imaging, retrieved 2026] PIUR IMAGING Receives FDA Clearance for PIUR tUS inside | https://www.piurimaging.com/post/piur-imaging-receives-fda-clearance-for-revolutionary-3d-ultrasound-technology-piur-tus-infinity-n
[LISAvienna] PIUR launches carotid angiography | https://www.lisavienna.at/life-sciences/news/detail/piur-launches-carotid-angiography/
[Grand View Research, 2024] Ultrasound Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/ultrasound-market
[Radiological Society of North America, 2023] Addressing the Radiologist Shortage | https://www.rsna.org/news/2023/june/radiologist-shortage
[PitchBook] Butterfly Network Inc. Company Profile | https://pitchbook.com/profiles/company/116900-10
Articles about PIUR IMAGING
- PIUR Imaging Upgrades the Ultrasound Machines Hospitals Already Own — With FDA clearance for its AI-powered 3D software and a GE HealthCare partnership, the Austrian medtech is betting on retrofitting the installed base.